Dexniguldipine hydrochloride inhibits growth of human HT-29 colon carcinoma cells and expression of protein kinase C Δ and ζ

Y. Qin, Y. Tang, A. V. Schally, B. S. Beckman

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Previous studies have implicated protein kinase C (PKC) in colon carcinogenesis, but a clear understanding of the role of PKC in colon cancer is lacking. The purpose of this study was to investigate the effects of dexniguldipine hydrochloride (DNIG) on the in vitro growth of HT-29 human colon carcinoma cells and the expression of PKC isoforms. DNIG is a selective inhibitor of PKC that binds specifically to the regulatory region and is also a potent antineoplastic drug with an ability to reverse multidrug resistance. DNIG (1.6-25 μM) decreased the number of HT-29 cells in culture in a time- and dose-dependent manner with an EC50 of 1.4 μM on day 3. Predominant PKC isoforms expressed in HT-29 cells were identified as Δ and ζ by immunoblotting. The expression of PKC Δ and ζ was inhibited significantly by DNIG (0.16-1.25 μM). These results suggest that the suppression of the growth of HT-29 colon carcinoma cells by DNIG involves the inhibition of the expression of PKC Δ and ζ.

Original languageEnglish (US)
Pages (from-to)1073-1077
Number of pages5
JournalInternational journal of oncology
Volume7
Issue number5
StatePublished - Dec 1 1995
Externally publishedYes

Keywords

  • Colon carcinoma
  • Dexniguldipine
  • Protein kinase C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Dexniguldipine hydrochloride inhibits growth of human HT-29 colon carcinoma cells and expression of protein kinase C Δ and ζ'. Together they form a unique fingerprint.

Cite this